NO20034031L - Substituerte pyrazol- og tiazolpyrimidiner - Google Patents

Substituerte pyrazol- og tiazolpyrimidiner

Info

Publication number
NO20034031L
NO20034031L NO20034031A NO20034031A NO20034031L NO 20034031 L NO20034031 L NO 20034031L NO 20034031 A NO20034031 A NO 20034031A NO 20034031 A NO20034031 A NO 20034031A NO 20034031 L NO20034031 L NO 20034031L
Authority
NO
Norway
Prior art keywords
compounds
diseases
disease
treatment
tinnitus
Prior art date
Application number
NO20034031A
Other languages
English (en)
Other versions
NO20034031D0 (no
Inventor
Matthias Gerlach
Martin Fuhr
Corinna Sundermann
Nee Maul
Utz-Peter Jagusch
Bernd Sundermann
Adriaan P Ijzerman
Miriam Dissen De Groote
Original Assignee
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001112197 external-priority patent/DE10112197A1/de
Priority claimed from DE2001153344 external-priority patent/DE10153344A1/de
Application filed by Univ Leiden filed Critical Univ Leiden
Publication of NO20034031D0 publication Critical patent/NO20034031D0/no
Publication of NO20034031L publication Critical patent/NO20034031L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives substituerte pyrazolopyrimidiner og tiazolopyrimidiner med den generelle formel (IA), (IB) og (II). en fremgangsmåte for deres fremstilling, substansbiblioteker inneholdende forbindelsene, medikamenter inneholdende forbindelser samt anvendelsen av forbindelsene ved fremstilling av medikamenter for behandling av smerte, epilepsi, schizofreni, neurodegenerative sykdommer og særlig Alzheimers sykdom, Huntingtons sykdom og Parkinsons sykdom, for behandling av cerebral ischemi og infarkter, psykoser forårsaket av økede aminosyrenivåer, cerebralt ødem, tilstander forårsaket av en under tilførsel til sentralnervesystemet, særlig ved hypoksi og spesielt nyfødt hypoksi og anoksi, for behandling av AIDS-relatert demens, encefalomyelitt, Tourettes syndrom, perinatal asfyksi, tinnitus, neuropatisk smerte, sykdommer i åndedrettssystemet, kreft, kardial arrytmi, irnmunlidelser og sykdommer, inflammatoriske tilstander og sykdommer, nyresvikt, søvnløshet, slag, tromboser, urininkontinens, diabetes, psoriasis, septisk sjokk, cerebralt trauma, laukom og/eller kongestiv hjertesvikt. Det beskrives videre farmasøytiske preparater inneholdende forbindelsene.
NO20034031A 2001-03-14 2003-09-11 Substituerte pyrazol- og tiazolpyrimidiner NO20034031L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2001112197 DE10112197A1 (de) 2001-03-14 2001-03-14 Substituierte Pyrazolo- und Thiazolopyrimidine
DE2001153344 DE10153344A1 (de) 2001-10-29 2001-10-29 Verwendung von substituierten Pyrazolopyrimidinen als Liganden von Nucleosid-Transport-Proteinen und/oder von Purinorezeptoren
PCT/EP2002/002722 WO2002072585A2 (de) 2001-03-14 2002-03-13 Substituierte pyrazolo- und thiazolopyrimidine als analgetika

Publications (2)

Publication Number Publication Date
NO20034031D0 NO20034031D0 (no) 2003-09-11
NO20034031L true NO20034031L (no) 2003-10-21

Family

ID=26008763

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034031A NO20034031L (no) 2001-03-14 2003-09-11 Substituerte pyrazol- og tiazolpyrimidiner

Country Status (25)

Country Link
US (1) US7135568B2 (no)
EP (2) EP1368355B1 (no)
JP (1) JP2004527508A (no)
KR (1) KR20030082982A (no)
CN (1) CN1318422C (no)
AT (2) ATE404568T1 (no)
AU (1) AU2002302419B2 (no)
BR (1) BR0208244A (no)
CA (1) CA2440760C (no)
CY (1) CY1105507T1 (no)
CZ (1) CZ20032474A3 (no)
DE (2) DE50212652D1 (no)
DK (1) DK1368355T3 (no)
ES (2) ES2263779T3 (no)
HK (1) HK1061034A1 (no)
HU (1) HUP0401211A3 (no)
IL (2) IL157895A0 (no)
MX (1) MXPA03008291A (no)
NO (1) NO20034031L (no)
NZ (2) NZ540574A (no)
PL (1) PL364388A1 (no)
PT (1) PT1368355E (no)
RU (1) RU2003129060A (no)
SK (1) SK11542003A3 (no)
WO (1) WO2002072585A2 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447100B2 (en) 2002-08-26 2016-09-20 Takeda Pharmaceutical Company, Ltd. Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI325865B (en) * 2003-02-27 2010-06-11 Palau Pharma Sa Pyrazolopyridine derivatives
GB0404434D0 (en) 2004-02-27 2004-03-31 Novartis Ag Organic compounds
US20080287405A1 (en) * 2004-05-14 2008-11-20 Thannickal Victor J Compositions and Methods Relating to Protein Kinase Inhibitors
AR050188A1 (es) * 2004-08-03 2006-10-04 Uriach Y Compania S A J Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen
EP1736475A1 (en) * 2005-06-21 2006-12-27 Ferrer Internacional, S.A. Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates
KR100838692B1 (ko) 2007-07-11 2008-06-16 한국화학연구원 7-(3′,4′-디알콕시페닐)-4,5,6,7-테트라히드로피라졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는천식 및 만성폐쇄성 폐질환을 포함한 염증관련 질환,관절염, 아토피 피부염, 암 및 뇌질환의 치료 및 예방을위한 약제학적 조성물
JP5584626B2 (ja) * 2008-01-24 2014-09-03 アンドレイ・アレクサンドロビッチ・イワシェンコ ２−アルキルアミノ−３−（アリールスルホニル）−シクロアルキル［ｅ又はｄ］ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製の方法及び使用
EP2248814A4 (en) * 2008-01-24 2011-01-12 Alla Chem Llc SUBSTITUTED CYCLOALKAN [E AND D] PYRAZOLO [1,5-A] PYRIMIDINES / ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS AND PROCESS FOR THEIR PREPARATION AND THEIR USE
CA2755968C (en) * 2008-10-06 2019-03-19 Andrey Alexandrovich Ivashchenko Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof
CA2747750A1 (en) * 2008-12-22 2010-07-01 Theodros Asberom Gamma secretase modulators
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
CN102775412B (zh) * 2012-08-21 2013-05-01 四川大学 一种镇静催眠的化合物及其制备方法和用途
CN102977106B (zh) * 2012-12-12 2014-12-10 中国药科大学 一类具有外周镇痛作用的κ阿片受体激动剂
JP6449845B2 (ja) 2013-03-15 2019-01-09 クロモセル コーポレイション 疼痛の処置のためのナトリウムチャネルモジュレーター
KR20160054570A (ko) 2013-09-10 2016-05-16 크로모셀 코포레이션 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자
WO2016123629A1 (en) * 2015-01-30 2016-08-04 Vanderbilt University Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
BR112018007664B1 (pt) 2015-10-16 2023-12-19 Eisai R&D Management Co., Ltd Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer
WO2018133835A1 (en) * 2017-01-20 2018-07-26 National Institute Of Biological Sciences, Beijing Nucleoside analogue regulating mammalian circadian rhythm
US10919891B2 (en) * 2017-04-27 2021-02-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN113354644B (zh) * 2020-03-04 2023-07-04 烟台药物研究所 一类用作dpp-iv抑制剂的吡唑并嘧啶结构的化合物及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847256A (en) * 1986-10-16 1989-07-11 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
EP0264773A1 (en) 1986-10-16 1988-04-27 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines
ZA903588B (en) * 1989-05-16 1991-02-27 Merrell Dow Pharma Excitatory amino acid antagonists
GB9206266D0 (en) * 1992-03-23 1992-05-06 Merck Sharp & Dohme Therapeutic agents
FR2717812B1 (fr) * 1994-03-28 1996-05-10 Rhone Poulenc Rorer Sa Indeno[1,2-e]pyrazine-4-ones, leur préparation et les médicaments les contenant.
FR2722786B1 (fr) * 1994-07-20 1996-08-23 Rhone Poulenc Rorer Sa Derives de 4-hydroxy-3-phenyl-indeno(1,2-b)pyridine-2(1h)- one, leur preparation et les medicaments les contenant
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
JP2003288537A (ja) 2000-09-25 2003-10-10 Everyd.Com:Kk 商品宅配システムおよび方法
DE10112197A1 (de) 2001-03-14 2002-09-19 Gruenenthal Gmbh Substituierte Pyrazolo- und Thiazolopyrimidine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447100B2 (en) 2002-08-26 2016-09-20 Takeda Pharmaceutical Company, Ltd. Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents

Also Published As

Publication number Publication date
EP1368355A2 (de) 2003-12-10
HUP0401211A3 (en) 2008-03-28
NZ540574A (en) 2006-11-30
CN1507447A (zh) 2004-06-23
WO2002072585A2 (de) 2002-09-19
US20040127508A1 (en) 2004-07-01
CY1105507T1 (el) 2010-04-28
PT1368355E (pt) 2006-09-29
PL364388A1 (en) 2004-12-13
HUP0401211A2 (hu) 2004-10-28
EP1368355B1 (de) 2006-06-07
ES2263779T3 (es) 2006-12-16
SK11542003A3 (sk) 2004-07-07
IL157895A0 (en) 2004-03-28
AU2002302419B2 (en) 2007-01-18
CN1318422C (zh) 2007-05-30
CA2440760C (en) 2010-02-09
CA2440760A1 (en) 2002-09-19
EP1637533B1 (de) 2008-08-13
DE50207103D1 (en) 2006-07-20
ATE328886T1 (de) 2006-06-15
US7135568B2 (en) 2006-11-14
CZ20032474A3 (cs) 2003-12-17
WO2002072585A3 (de) 2003-02-20
KR20030082982A (ko) 2003-10-23
DK1368355T3 (da) 2006-10-09
MXPA03008291A (es) 2003-12-11
JP2004527508A (ja) 2004-09-09
HK1061034A1 (en) 2004-09-03
IL157895A (en) 2009-12-24
ATE404568T1 (de) 2008-08-15
EP1637533A1 (de) 2006-03-22
NZ528639A (en) 2005-07-29
BR0208244A (pt) 2004-03-02
NO20034031D0 (no) 2003-09-11
ES2311920T3 (es) 2009-02-16
DE50212652D1 (de) 2008-09-25
RU2003129060A (ru) 2005-04-10

Similar Documents

Publication Publication Date Title
NO20034031L (no) Substituerte pyrazol- og tiazolpyrimidiner
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
WO2003053330A3 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
UA83899C2 (uk) Сполуки імідазолу для лікування нейродегенеративних розладів
WO2006040451A2 (fr) Nouveaux derives de 9h-pyrido (2, 3-b) indole en tant qu'inhibiteurs de cdk et gsk3 , leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
NO174772C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive piperazinylderivater
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
ATE447571T1 (de) Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken; verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
ATE253918T1 (de) Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
JPS5976086A (ja) プテリジン化合物
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
MY142431A (en) Oxadiazolones, processes for their preparation and their use as pharmaceuticals
CA2534532A1 (en) Compounds for the treatment of neurodegenerative disorders
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
EP1958939A3 (en) Pyrazole-amine compounds for the treatment of neurodegenerative disorders
US11427590B2 (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases
WO2007034326A3 (en) Imidazole compounds for the treatment of neurological disorders
US11897876B2 (en) Isoxazolidines as RIPK1 inhibitors and use thereof
CN115974854B (zh) 苯酚基烯基苯酞吡唑酮类化合物及其制备方法和用途
JP6532880B2 (ja) Ｐｄｅ１阻害剤としてのヘキサヒドロフロピロール
CA2534529A1 (en) Oxazole compounds for the treatment of neurodegenerative disorders
JP2020520925A (ja) 化合物、組成物および方法
WO2005095361A8 (en) Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application